LGL Partners LLC Makes New Investment in VanEck Biotech ETF $BBH

LGL Partners LLC purchased a new stake in shares of VanEck Biotech ETF (NASDAQ:BBH) in the second quarter, Holdings Channel reports. The firm purchased 11,308 shares of the company’s stock, valued at approximately $2,298,000. VanEck Biotech ETF comprises about 0.9% of LGL Partners LLC’s portfolio, making the stock its 17th largest position.

Other hedge funds and other institutional investors have also bought and sold shares of the company. First PREMIER Bank bought a new position in VanEck Biotech ETF in the 2nd quarter valued at $91,000. Proficio Capital Partners LLC purchased a new position in shares of VanEck Biotech ETF in the 2nd quarter worth about $5,183,000. Nwam LLC bought a new position in VanEck Biotech ETF during the second quarter valued at about $18,614,000. JNBA Financial Advisors bought a new position in VanEck Biotech ETF during the second quarter valued at about $122,000. Finally, Headlands Technologies LLC purchased a new stake in VanEck Biotech ETF during the second quarter worth about $1,576,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Performance

Shares of BBH stock opened at $235.50 on Tuesday. The company has a 50 day moving average of $213.87 and a 200-day moving average of $197.38. VanEck Biotech ETF has a 12-month low of $160.91 and a 12-month high of $244.35.

Insiders Place Their Bets

In other VanEck Biotech ETF news, major shareholder Sardar Biglari sold 2,749 shares of the company’s stock in a transaction dated Thursday, July 16th. The shares were sold at an average price of $16.70, for a total transaction of $45,908.30. Following the sale, the insider directly owned 3,549,961 shares of the company’s stock, valued at $59,284,348.70. This represents a 0.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 10,493 shares of company stock valued at $175,335.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.